Brii Bio announces positive end-of-treatment results from phase 2b ENRICH & ENHANCE studies to treat chronic hepatitis B: Durham, North Carolina Monday, July 6, 2026, 18:00 Hrs [I ...
Vietnam Investment Review on MSN
Brii Bio phase 2b hepatitis B data from ENRICH and ENHANCE studies released
DURHAM, N.C. and BEIJING, July 3, 2026 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient ...
Global hepatitis report 2024: action for access in low- and middle-income countries. World Health Organization. Retrieved from ...
Headquartered in the south of France, with a significant global footprint spanning multiple regions and customers across international markets, MANE is known for its innovation, technical expertise ...
Discusses Phase III Program Design and Durable Cardiac Improvements in Friedreich's Ataxia June 29, 2026 2:00 PM ...
Both Annamycin dose arms outperformed control on the primary endpoint of complete remission (CR): 43% and 36% versus 12% — ...
Every investor is looking for opportunities, but finding promising stocks and deciding when to buy is rarely a simple task. Successful investing often depends on separating temporary market moves from ...
The owner of five dogs who mauled a man to death in March 2025 pleaded guilty to negligent homicide and multiple counts of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results